MBX Biosciences IPO

MBX Biosciences is a clinical-stage biopharmaceutical company that specializes in developing therapies to treat rare endocrine diseases and metabolic disorders.

Register for Details

For more details on financing and valuation of private companies similar to MBX Biosciences before its , register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn More About MBX Biosciences

To invest in MBX Biosciences pre-IPO

Can you invest in MBX Biosciences pre-IPO?

You may invest in MBX Biosciences as it is a public company listed on the NASDAQ with ticker MBX. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.

Can you sell shares of MBX Biosciences before it goes public?

You can no longer sell shares of MBX Biosciences on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.

What is the pre-IPO value of my MBX Biosciences shares?

Forge can no longer determine the value of MBX Biosciences shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.

Is MBX Biosciences a publicly traded company?

MBX Biosciences became a public company following its IPO on 09/12/2024 and is now traded on the NASDAQ under the ticker MBX.

To learn more about MBX Biosciences potential IPO

Will MBX Biosciences go IPO?

MBX Biosciences became a public company following its IPO on 09/12/2024 and is now traded on the NASDAQ under the ticker MBX.

What is MBX Biosciences’ IPO price?

The IPO price of MBX Biosciences is not currently available.

When was MBX Biosciences founded?

MBX Biosciences was founded in 2019.

What is MBX Biosciences funding to date?

MBX Biosciences has raised $216.64MM to date.

Who are MBX Biosciences’s major investors?

Deep Track Capital
Driehaus Capital Management
Ra Capital Management
Norwest Venture Partners
Nea
Wellington Management
T. Rowe Price Associates
Twilight Venture Partners
Orbimed
Frazier Life Sciences
Biocrossroads
IU Ventures
Frazier Healthcare Partners

MBX Biosciences Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
08/05/2024 Series C $63.5MM $xx.xx $316.71MM Deep Track Capital, Driehaus Capital Management, Frazier Life Sciences, Orbimed, T. Rowe Price Associates, Wellington Management
Price per Share
$xx.xx
Shares Outstanding
61,650,480
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Deep Track Capital, Driehaus Capital Management, Frazier Life Sciences, Orbimed, T. Rowe Price Associates, Wellington Management
11/14/2022 Series B $116.32MM $xx.xx $235.08MM Frazier Life Sciences, Nea, Norwest Venture Partners, Orbimed, Ra Capital Management, Wellington Management
Price per Share
$xx.xx
Shares Outstanding
129,240,032
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Frazier Life Sciences, Nea, Norwest Venture Partners, Orbimed, Ra Capital Management, Wellington Management
07/27/2020 Series A $36.82MM $xx.xx $61.37MM Biocrossroads, Frazier Healthcare Partners, IU Ventures, Nea, Orbimed, Twilight Venture Partners
Price per Share
$xx.xx
Shares Outstanding
53,598,587
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Biocrossroads, Frazier Healthcare Partners, IU Ventures, Nea, Orbimed, Twilight Venture Partners
Updated on: Dec 21, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.